
The US Food and Drug Administration said Tuesday it has approved the first drug made with a 3-D printer -- pills for treating epilepsy.
The Ohio-based company Aprecia Pharmaceuticals said its system can produce doses of up to 1,000 mg per tablet.
It said the product is a "porous formulation" that dissolves with just a sip of liquid, making it convenient for people who have trouble swallowing pills or for getting children to take medication.
FDA spokeswoman Sandy Walsh confirmed to AFP that the medication known as Spritam is the first made with a 3-D printer that the agency has approved.
Spritam, or Levetiracetam, has already been on the market for years in other formats, Walsh said.
Aprecia, which is not listed, plans to start distributing the medication in the first quarter of next year.
The FDA had already given the green light to other medical products made with such 3-D technology, such as prosthetic devices.
Aprecia said on its website that in coming years it plans to develop other kinds of medication with the new technology.
The health care industry is turning more and more to 3-D printers to produce custom-made implants for patients with rare pathologies or with certain kinds of injuries.
GMT 18:35 2018 Thursday ,11 January
Syrian refugee sets himself ablaze at UN office in LebanonGMT 18:48 2018 Tuesday ,09 January
Novo Nordisk woos Belgian nano-drug makerGMT 17:54 2017 Wednesday ,27 December
Medical evacuations begin from besieged Syria rebel bastionGMT 12:14 2017 Monday ,25 December
MoHAP successfully conducts cochlear implant operationGMT 18:24 2017 Sunday ,24 December
Palestinian conjoined twins arrive in RiyadhGMT 19:05 2017 Monday ,18 December
new! magazine names fitness & food editorGMT 17:03 2017 Wednesday ,29 November
Spain reports case of 'mad cow disease'GMT 14:05 2017 Saturday ,11 November
EU can't agree on new licence for controversial glyphosate weedkiller
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Send your comments
Your comment as a visitor